ReviewFrontiers in immunology2026
The role of immune cells in Hantaan-induced hemorrhagic fever with renal syndrome.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hemorrhagic fever with renal syndrome (HFRS) is a severe and often fatal zoonotic disease primarily caused by the Hantaan virus (HTNV), a member of the Orthohantavirus genus. Although immune cells are known to play critical roles in HTNV-induced HFRS, the detailed dynamic changes, phenotypic alterations, and functional profiles of distinct immune subsets over the course of the disease remain poorly understood. In this review, we summarize current understanding of key immune populations during HTNV infection, including monocytes, macrophages, dendritic cells (DCs), natural killer (NK) cells, neutrophils, T cells and B cells. We highlight a central immunological duality in which these cells are necessary for viral clearance while also participating in immunopathological tissue damage. By integrating clinical and mechanistic insights, we present a detailed framework for understanding how the balance between protective immunity and immunopathology determines disease outcome. Recognizing these complex dynamics will be crucial for directing future studies and determining potential therapeutic targets in HFRS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.